Brief: FDA Approves XDEMVY™ (Lotilaner Ophthalmic Solution) 0.25% For The Treatment Of Demodex Blepharitis
25/07/2023 12:35
July 25 (Reuters) - Tarsus Pharmaceuticals Inc TARS.O :
* FDA APPROVES XDEMVY™ (LOTILANER OPHTHALMIC SOLUTION) 0.25%
FOR
THE TREATMENT OF DEMODEX BLEPHARITIS
* TARSUS PHARMACEUTICALS INC - XDEMVY EXPECTED TO BE
AVAILABLE BY
PRESCRIPTION BY END OF AUGUST 2023
* TARSUS PHARMACEUTICALS INC - XDEMVY EXPECTED TO BE
AVAILABLE BY
PRESCRIPTION BY END OF AUGUST 2023
Source text for Eikon: ID:nGNX75b86Y
Further company coverage: TARS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tarsus Pharmaceuticals
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Tarsus Pharmaceuticals Files For Offering Of Up To 2.91 Million Shares Of Common Stock By Selling Stockholders
U.S. RESEARCH ROUNDUP-Argan, Mastec, Oracle
Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition (updated)